What You Should Know:
– Deciphex, a leading digital pathology company based in Dublin, Ireland, has announced a collaborative effort with Novartis, a prominent multinational pharmaceutical corporation.
– The strategic partnership focuses on developing innovative artificial intelligence (AI) solutions aimed at revolutionizing preclinical pathology assessments within the drug discovery and development process.
Optimizing Preclinical Pathology with AI
The collaboration centers on creating a suite of AI-powered tools designed to streamline and enhance the evaluation of pathology data in toxicology and efficacy studies, critical phases of drug development.
Here’s how this partnership will function:
- Leveraging Expertise: The collaboration combines Deciphex’s proficiency in unsupervised AI model development with Novartis’s extensive experience in AI models, digital pathology databases, and related tools.
- Building on Existing Assets: The project will utilize Deciphex’s existing intellectual property alongside Novartis’s resources to create potentially groundbreaking algorithms for accurate lesion identification and quantification within drug discovery applications.
Combining Expertise for Innovation
The collaboration will prioritize several key objectives:
- AI-powered Lesion Detection Tools: Developing a comprehensive suite of AI tools specifically designed to detect lesions across various tissue types and species, applicable to both Good Laboratory Practice (GLP) and non-GLP studies.
- Regulatory Compliance: Ensuring the developed AI tools meet the most recent regulations and guidelines governing AI development processes, paving the way for wider adoption.
- Digital Pathology Archive Creation: Deciphex will leverage its next-generation scanning services to digitize Novartis’s vast collection of tissue slides, creating a valuable digital library for future research and analysis.
“This partnership underscores our commitment to advancing healthcare through the development of cutting-edge solutions that address critical challenges in drug development lifecycles.Novartis is committed to innovating AI-based approaches with potential to accelerate drug discovery and development and bring life-changing medicines to patients faster,” said Dr. Donal O’Shea,” CEO of Deciphex.
